EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA

Lorena C S Chaves, Nichole Orr-Burks, Daryll Vanover, Varun V Mosur, Sarah R Hosking, Pramod Kumar E K, Hyeyoon Jeong, Younghun Jung, José A F Assumpção, Hannah E Peck, Sarah L Nelson, Kaitlyn N Burke und 8 weitere

PLOS Pathogens · 05.07.2024 · 20 (7) · e1012345

DOI: 10.1371/journal.ppat.1012345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 05.07.2024. Verfasst von Lorena C S Chaves und 19 weiteren Autor:innen. Beteiligte Einrichtung: Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, United States of Ame…. Hauptthemen laut MEDLINE: RNA, Viral, RNA, Messenger, CRISPR-Cas Systems, RNA Stability. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Defense Sciences Office, DARPA, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR-Cas13 system has been proposed as an alternative treatment of viral infections. However, for this approach to be adopted as an antiviral, it must be optimized until levels of efficacy rival or exceed the performance of conventional approaches. To take steps toward this goal, we evaluated the influenza viral RNA degradation patterns resulting from the binding and enzymatic activity of mRNA-encoded LbuCas13a and two crRNAs from a prior study, targeting PB2 genomic and messenger RNA. We found that the genome targeting guide has the potential for significantly higher potency than originally detected, because degradation of the genomic RNA is not uniform across the PB2 segment, but it is augmented in proximity to the Cas13 binding site. The PB2 genome targeting guide exhibited high levels (>1 log) of RNA degradation when delivered 24 hours post-infection in vitro and maintained that level of degradation over time, with increasing multiplicity of infection (MOI), and across modern influenza H1N1 and H3N2 strains. Chemical modifications to guides with potent LbuCas13a function, resulted in nebulizer delivered efficacy (>1–2 log reduction in viral titer) in a hamster model of influenza (Influenza A/H1N1/California/04/09) infection given prophylactically or as a treatment (post-infection). Maximum efficacy was achieved with two doses, when administered both pre- and post-infection. This work provides evidence that mRNA-encoded Cas13a can effectively mitigate Influenza A infections opening the door to the development of a programmable approach to treating multiple respiratory infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, ViralRNA, MessengerCRISPR-Cas SystemsRNA StabilityInfluenza, HumanAnimalsHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeOrthomyxoviridae InfectionsAntiviral AgentsDogsCricetinaeViral ProteinsMesocricetusMadin Darby Canine Kidney Cells

Substanzen

RNA, ViralRNA, MessengerAntiviral AgentsViral Proteins

Autor:innen und Institutionen

  • Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, United States of America.
  • Department of Infectious Diseases, College of Veterinary Medicine University of Georgia, Athens, Georgia, United States of America.
  • Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Emory Integrated Computational Core, Emory University, Atlanta, Georgia, United States of America.
  • Duke Human Vaccine Institute Duke University School of Medicine, Durham, North Carolina, United States of America.

ORCID-Profile: Philip J Santangelo

Förderung

  • NIAID NIH HHS
  • Defense Sciences Office, DARPA
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • School of Medicine, Emory University

Zitieren

APA

Chaves, L. C. S., Orr-Burks, N., Vanover, D., Mosur, V. V., Hosking, S. R., Kumar E K, P., Jeong, H., Jung, Y., Assumpção, J. A. F., Peck, H. E., Nelson, S. L., Burke, K. N., Garrison, M. A., Arthur, R. A., Claussen, H., Heaton, N. S., Lafontaine, E. R., Hogan, R. J., Zurla, C., & Santangelo, P. J. (2024). mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA. PLOS Pathogens, 20(7), e1012345. https://doi.org/10.1371/journal.ppat.1012345

Vancouver

Chaves LCS, Orr-Burks N, Vanover D, Mosur VV, Hosking SR, Kumar E K P, et al. mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA. PLOS Pathogens. 2024;20(7):e1012345. doi:10.1371/journal.ppat.1012345

BibTeX
@article{Chaves2024,
  author = {Chaves, Lorena C S and Orr-Burks, Nichole and Vanover, Daryll and Mosur, Varun V and Hosking, Sarah R and Kumar E K, Pramod and Jeong, Hyeyoon and Jung, Younghun and Assumpção, José A F and Peck, Hannah E and Nelson, Sarah L and Burke, Kaitlyn N and Garrison, McKinzie A and Arthur, Robert A and Claussen, Henry and Heaton, Nicholas S and Lafontaine, Eric R and Hogan, Robert J and Zurla, Chiara and Santangelo, Philip J},
  title = {mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA},
  journal = {PLOS Pathogens},
  year = {2024},
  volume = {20},
  number = {7},
  pages = {e1012345},
  doi = {10.1371/journal.ppat.1012345}
}
Kostenlos starten →